Sign up
Pharma Capital

Avacta Group appoints Immunocore’s Eliot Forster as non-executive chairman

The AIM-listed firm said Dr Trevor Nichols, who has acted as chairman of the board since January 2014, will remain on the board as non-executive director
handshake
The company, which develops Affimer biotherapeutics and reagents, said Forster brings over 25 years of experience in the pharmaceutical and biotechnology industry

Avacta Group Plc (LON:AVCT) has announced the appointment of Dr Eliot Forster as non-executive chairman to the board with immediate effect.

The AIM-listed firm said Dr Trevor Nichols, who has acted as chairman of the board since January 2014, will remain on the board as non-executive director.

READ: Avacta hails encouraging results to tie-up with Finnish firm, shares gain

The company, which develops Affimer biotherapeutics and reagents, said Forster brings over 25 years of experience in the pharmaceutical and biotechnology industry.

Avacta said most recently he led Immunocore as chief executive officer to become a world-leading immuno-oncology biotech, raising over £230mln in equity and non-dilutive funding as well as securing partnerships with AstraZeneca PLC (LON:AZN) and the Bill & Melinda Gates Foundation.

The early part of Forster's career was at GSK and then he went on to hold a number of senior roles in Pfizer Inc (NYSE:PFE)

Alastair Smith, CEO of Avacta Group, said: “We have an exciting opportunity to build a world-leading and highly valuable biotech based on the Affimer platform.”

He added: ”Eliot's considerable experience, expertise and network will make a material difference to achieving that goal and to delivering maximum value to shareholders.”

View full AVCT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.